+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 180 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 4118838
Description Jump to:
The global antiviral drugs market size is expected to reach USD 62.05 billion by 2030, registering a CAGR of -1.99% from 2023 to 2030. This is attributed to the rising prevalence of viral diseases and growing government initiatives pertaining to the development of novel therapeutics to reduce the spread of infections. Furthermore, an increase in R&D efforts and the expansion of more recent & updated details, such as vaccinations and combined therapy, are projected to propel the growth of the market. Potential viral pandemics highlight the need for broad-spectrum antiviral drugs, such as direct-acting antivirals, that can be immediately deployed on a massive scale to halt viral spread until suitable vaccinations are created. Introducing blockbuster therapeutics for antiviral drugs has been transformative in treating various viral infections.

These drugs have demonstrated significant efficacy, widespread use, and substantial revenue generation for pharmaceutical companies. One prominent example is the introduction of Direct-acting Antivirals (DAAs) for the treatment of hepatitis C drugs, such as Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), and Epclusa (sofosbuvir/velpatasvir), revolutionized the field by providing high cure rates, shorter treatment durations, and fewer side effects compared to previous therapies. These drugs achieved blockbuster status due to their effectiveness in curing hepatitis C and addressing a significant unmet medical need. Government initiatives for antiviral drugs include funding for R&D, streamlining regulatory processes for approval and emergency use authorizations, strategic stockpiling for preparedness, and collaborations with industry & academic institutions to accelerate development and ensure accessibility of effective antiviral treatments.

For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, granted around USD 577 million to launch nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. Moreover, increasing collaborations between government bodies and key players are anticipated to fuel the growth of R&D activities for developing novel antiviral drugs. For instance, in June 2021, Merck & Co., Inc. entered into a procurement agreement with the U.S. government for molnupiravir, an investigational antiviral for COVID-19 treatment. According to the agreement, the company will receive USD 1.2 billion to supply around 1.7 million drug courses to the U.S. government if molnupiravir receives emergency use authorization or approval by the U.S. FDA.

Furthermore, market entities are undertaking strategic initiatives to address the growing demand for clinical tests. Major players are involved in the acquisition of regional players to strengthen their position in the market. Thus, there is significant competition among players in this region. Players in the market are focusing on developing new products. For instance, as of June 2023, over 900 studies are ongoing in phases 2, 3, and 4 of clinical trials for antiviral drug development. Moreover, in April 2023, PharmaMar initiated the Nereida clinical trial using plitidepsin for the treatment of immunosuppressed patients suffering from COVID-19, with trials being approved in Spain, Italy, France, Poland, Hungary, Greece, and Portugal.

Antiviral Drugs Market Report Highlights

  • The branded type segment dominated the market in 2022 as they are widely adopted due to their proven efficacy, safety profile, and endorsement by healthcare authorities
  • On the basis of drug class, the protease inhibitors segmentdominated the market in 2022 owing to the rising need for effective therapeutics due to the increasing prevalence of chronic diseases, such as HIV/AIDS
  • Based on distribution channel, the hospital pharmacy segment held the largest market share in 2022owing to an increasing number of people suffering from diseases, a rapidly aging population, and a growing number of hospitalizations
  • North America has established a strong regional position in the market due to the presence of well-established healthcare infrastructure, a high prevalence of viral diseases, and rapid advancements in therapeutics

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Increasing prevalence of viral infections
3.4.2. Increasing government initiatives for viral infections
3.4.3. Increasing geriatric population
3.5. Market Restraint Analysis
3.5.1. High cost of treatment
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.7. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Antiviral Drugs Market: Type Movement Analysis
4.2. Branded
4.2.1. Branded Market, 2018 - 2030 (USD Million)
4.3. Generics
4.3.1. Generics Market, 2018 - 2030 (USD Million)
Chapter 5. Drug Class Business Analysis
5.1. Antiviral Drugs Market: Drug Class Movement Analysis
5.2. DNA Polymerase Inhibitors
5.2.1. DNA Polymerase Inhibitors Market, 2018 - 2030 (USD Million)
5.3. Reverse Transcriptase Inhibitors
5.3.1. Reverse Transcriptase Inhibitors Market, 2018 - 2030 (USD Million)
5.4. Protease Inhibitors
5.4.1. Protease Inhibitors Market, 2018 - 2030 (USD Million)
5.5. Neuraminidase Inhibitors
5.5.1. Neuraminidase Inhibitors Market, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Distribution Channel Business Analysis
6.1. Antiviral Drugs Market: Distribution Channel Movement Analysis
6.2. Hospital Pharmacy
6.2.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
6.4. Online Pharmacy
6.4.1. Online Pharmacy Market, 2018 - 2030 (USD Million)
Chapter 7. Application Business Analysis
7.1. Antiviral Drugs Market: Application Movement Analysis
7.2. Influenza
7.2.1. Influenza Market, 2018 - 2030 (USD Million)
7.3. HIV
7.3.1. HIV Market, 2018 - 2030 (USD Million)
7.4. Hepatitis
7.4.1. Hepatitis Market, 2018 - 2030 (USD Million)
7.5. Herpes
7.5.1. Herpes Market, 2018 - 2030 (USD Million)
7.6. Others
7.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Antiviral Drugs Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. U.S. Antiviral drugs Market, 2018 - 2030 (USD MILLION)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Reimbursement Scenario
8.2.4.6. Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.4. UK
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. France Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Reimbursement Scenario
8.3.10.6. Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. China Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. India Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. Reimbursement Scenario
8.4.8.6. Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Reimbursement Scenario
8.5.5.6. Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Reimbursement Scenario
8.6.6.6. Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.2.1. New Product Launch
9.2.2. Partnership
9.2.3. Acquisition
9.2.4. Collabboration
9.2.5. Funding
9.3. Key Company Market Share Analysis, 2022
9.4. Company Heat Map Analysis
9.5. Company Profiles
9.5.1. F. HOFFMANN-LA ROCHE LTD.
9.5.1.1. Company Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. GSK PLC.
9.5.2.1. Company Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. ABBVIE, INC.
9.5.3.1. Company Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. MERCK & CO., INC.
9.5.4.1. Company Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. JOHNSON & JOHNSON SERVICES, INC.
9.5.5.1. Company Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. BRISTOL-MYERS SQUIBB COMPANY
9.5.6.1. Company Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. CIPLA INC.
9.5.7.1. Company Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. AUROBINDO PHARMA
9.5.8.1. Company Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. DR. REDDY’S LABORATORIES LTD.
9.5.9.1. Company Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 Global Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 3 Global Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 4 Global Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 5 Global Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 6 Global Antiviral Drugs Market, by Region, 2018 - 2030 (USD Million)
Table 7 North America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 8 North America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 9 North America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 10 North America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 North America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 12 U.S. Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 13 U.S. Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 14 U.S. Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 15 U.S. Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 16 Canada Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 17 Canada Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 18 Canada Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Canada Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 20 Europe Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 21 Europe Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 22 Europe Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 23 Europe Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 24 Europe Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 25 Germany Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 26 Germany Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 27 Germany Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Germany Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 29 UK Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 30 UK Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 31 UK Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 UK Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 33 France Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 34 France Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 35 France Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 36 France Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 37 Italy Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 38 Italy Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 39 Italy Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Italy Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 41 Spain Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 42 Spain Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 43 Spain Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 Spain Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 45 Denmark Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 46 Denmark Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 47 Denmark Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 48 Denmark Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 49 Sweden Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 50 Sweden Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 51 Sweden Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Sweden Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 53 Norway Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 54 Norway Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 55 Norway Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 Norway Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 58 Asia Pacific Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 62 China Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 63 China Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 64 China Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 65 China Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 66 Japan Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 67 Japan Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 68 Japan Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 69 Japan Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 70 India Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 71 India Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 72 India Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 73 India Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 74 South Korea Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 75 South Korea Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 76 South Korea Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 77 South Korea Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 78 Australia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 79 Australia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 80 Australia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 81 Australia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 82 Thailand Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 83 Thailand Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 84 Thailand Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 85 Thailand Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 86 Latin America Antiviral Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 87 Latin America Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 88 Latin America Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 89 Latin America Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 90 Latin America Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 91 Brazil Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 92 Brazil Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 93 Brazil Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 94 Brazil Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 95 Mexico Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 96 Mexico Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 97 Mexico Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 98 Mexico Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 99 Argentina Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 100 Argentina Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 101 Argentina Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 102 Argentina Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 103 Middle East & Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 107 South Africa Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 108 South Africa Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 109 South Africa Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 110 South Africa Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 111 Saudi Arabia Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 112 Saudi Arabia Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 115 UAE Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 116 UAE Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 117 UAE Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 118 UAE Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
Table 119 Kuwait Antiviral Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 120 Kuwait Antiviral Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 121 Kuwait Antiviral Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 122 Kuwait Antiviral Drugs Market, by Application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain - Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Antiviral Drugs Market Segmentation
Fig. 8 Market Snapshot, 2022
Fig. 9 Market Trends & Outlook
Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
Fig. 16 Global Antiviral Drugs Market: Type Movement Analysis
Fig. 17 Global Antiviral Drugs Market, by Branded, 2018 - 2030 (USD Million)
Fig. 18 Global Antiviral Drugs Market, by Generics, 2018 - 2030 (USD Million)
Fig. 19 Global Antiviral Drugs Market: Drug Class Movement Analysis
Fig. 20 Global Antiviral Drugs Market, by DNA Polymerase Inhibitors, 2018 - 2030 (USD Million)
Fig. 21 Global Antiviral Drugs Market, by Reverse Transcriptase Inhibitors, 2018 - 2030 (USD Million)
Fig. 22 Global Antiviral Drugs Market, by Protease Inhibitors, 2018 - 2030 (USD Million)
Fig. 23 Global Antiviral Drugs Market, by Neuraminidase Inhibitors, 2018 - 2030 (USD Million)
Fig. 24 Global Antiviral Drugs Market, by Others, 2018 - 2030 (USD Million)
Fig. 25 Global Antiviral Drugs Market: Distribution Channel Movement Analysis
Fig. 26 Global Antiviral Drugs Market, by Hospital Pharmacy 2018 - 2030 (USD Million)
Fig. 27 Global Antiviral Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
Fig. 28 Global Antiviral Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
Fig. 29 Regional Marketplace: Key Takeaways
Fig. 30 Regional Outlook, 2022 & 2030
Fig. 31 Global Antiviral Drugs Market: Region Movement Analysis
Fig. 32 North America Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 33 U.S. Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 34 Canada Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 35 Europe Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 36 Germany Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 37 UK Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 38 France Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 39 Italy Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 40 Spain Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 41 Denmark Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 42 Sweden Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 43 Norway Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 44 Asia Pacific Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 45 Japan Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 46 China Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 47 India Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 48 Australia Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 49 South Korea Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 50 Thailand Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 51 Latin America Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 52 Brazil Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 53 Mexico Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 54 Argentina Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 55 Middle East and Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 56 South Africa Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 57 Saudi Arabia Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 58 UAE Antiviral Drugs Market, 2018 - 2030 (USD Million)
Fig. 59 Kuwait Antiviral Drugs Market, 2018 - 2030 (USD Million)

Companies Mentioned

  • F. HOFFMANN-LA ROCHE LTD.
  • GSK PLC.
  • ABBVIE, INC.
  • MERCK & CO., INC.
  • JOHNSON & JOHNSON SERVICES, INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • CIPLA INC.
  • AUROBINDO PHARMA
  • DR. REDDY’S LABORATORIES LTD.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030 - Product Image

Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Direct-acting Antiviral Drug Market by Type, Indication, Route, Distribution Channel - Global Forecast 2025-2030 - Product Image

Direct-acting Antiviral Drug Market by Type, Indication, Route, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030 - Product Image

Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030

  • Report
  • 296 Pages
  • Global
From
Antivirals Global Market Report 2024 - Product Image

Antivirals Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.